Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TTP273 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TTP273 300 mg daily (150 mg BID) | EXPERIMENTAL | Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks |
| TTP273 150 mg daily | EXPERIMENTAL | Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Two matching placebo tablets administered orally twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| TTP273 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * The subject has a 6 month diagnosis of Type 2 diabetes mellitus prior to screening and meets the American Diabetes Association (ADA) guidelines for Type 2 diabetes mellitus. * On a stable regimen of metformin monotherapy equivalent to at least 1000 mg/day for the last 3 months...
TTP273 is an investigational oral small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It was evaluated in a Phase 2 clinical trial in adults with the condition. It is not approved for any indication and remains in clinical development.
TTP273 targets GLP-1R, the glucagon-like peptide-1 receptor. GLP-1R is a receptor that mediates the effects of the gut hormone GLP-1 on glucose regulation. By acting on this receptor, TTP273 is designed as an oral small molecule approach to GLP-1 receptor activation.
TTP273 is being developed by vTv Therapeutics Inc., which trades under the ticker VTVT. The company sponsored the Phase 2 clinical trial of the drug in Type 2 Diabetes Mellitus.
TTP273 is in Phase 2 development. It has completed one Phase 2 trial in Type 2 Diabetes Mellitus. The drug is investigational and has not been approved by the FDA for any indication.
TTP273 has been studied in the Phase 2 trial NCT02653599, titled A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes. The trial enrolled 174 participants in the United States and is completed.
The Phase 2 trial NCT02653599 was a randomized, double-blind, placebo-controlled study of TTP273 given for 12 weeks to adults with Type 2 Diabetes Mellitus. It enrolled 174 participants aged 18 years and older in the United States and is completed.